NovoCure Ltd. (NASDAQ:NVCR) traded up 12.5% on Monday . The company traded as high as $8.51 and last traded at $8.46, with a volume of 566,982 shares. The stock had previously closed at $7.52.

A number of equities research analysts have weighed in on the stock. Wedbush cut their price objective on shares of NovoCure from $30.00 to $20.00 and set an “outperform” rating on the stock in a report on Friday. Deutsche Bank AG cut their price objective on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating on the stock in a report on Friday. Barclays PLC cut their price objective on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Friday. Zacks Investment Research cut shares of NovoCure from a “hold” rating to a “sell” rating in a report on Friday, May 13th. Finally, JMP Securities cut their price objective on shares of NovoCure from $43.00 to $34.00 and set a “market outperform” rating on the stock in a report on Friday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.43.

The stock has a 50-day moving average of $11.24 and a 200 day moving average of $12.76. The stock’s market cap is $675.37 million.

NovoCure (NASDAQ:NVCR) last posted its earnings results on Thursday, July 28th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.11. The business had revenue of $17.90 million for the quarter, compared to analyst estimates of $15.90 million. Analysts forecast that NovoCure Ltd. will post ($1.49) EPS for the current year.

In other NovoCure news, COO Michael J. Ambrogi sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $12.24, for a total transaction of $244,800.00. Following the transaction, the chief operating officer now owns 324,084 shares of the company’s stock, valued at approximately $3,966,788.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Other hedge funds and institutional investors have bought and sold shares of the company. Hartline Investment Corp acquired a new position in NovoCure during the fourth quarter worth approximately $1,143,000. Century Capital Management LLC acquired a new position in NovoCure during the fourth quarter worth approximately $2,970,000. Finally, Morgan Stanley acquired a new position in NovoCure during the fourth quarter worth approximately $9,619,000.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.